Using sirolimus to treat cystic lymphatic malformations in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the efficacy and safety of different doses of sirolimus, an immunosuppressant, in treating cystic lymphatic malformations in children aged 0 to 18. The condition is characterized by abnormal lymphatic vessel development, leading to fluid accumulation and swelling. By comparing various concentration gradients of sirolimus, the researchers hope to find a dosage that maximizes therapeutic benefits while minimizing side effects. The study is being conducted at the West China Hospital of Sichuan University.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Presenting a LM with the following characteristics:

  1. Male and female;
  2. Between 0 and 18 years of age;
  3. LM diagnosis was confirmed by local investigators and by consensus of our multidisciplinary vascular anomaly group at the West China Hospital of Sichuan University based on:

Biopsy; Compatible MRI findings; History and clinical features.

Exclusion Criteria:

1. Patients contraindicated for the administration of sirolimus (e.g., those with an allergy to sirolimus or other rapamycin analog)
2. Exposure to chemotherapy, embolization, corticosteroids, propranolol, sclerotherapy or any other investigational agents within 1 weeks before enrolment on study;
3. Patients had a history of a major surgery within 2 weeks before enrollment;
4. Patients who have a history of treatment with sirolimus or other mTOR inhibitor;
5. Any known evidence of significant local or systemic uncontrolled infection, defined as receiving intravenous antibiotics at the time of enrollment;
6. Concurrent severe and/or uncontrolled medical diseases that could compromise participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe malnutrition, chronic liver or renal disease, active upper gastrointestinal tract ulceration).
7. Impairment of gastrointestinal function or chronic gastrointestinal disease that may significantly alter the absorption of sirolimus.
8. Patients with inadequate liver function:

   Total bilirubin higher than or equal to 1.5 × the upper limit of the normal (ULN) for age and alanine aminotransferase and aspartate aminotransferase higher than or equal to 2.5 × the ULN for age.
9. Patients with inadequate renal function:

   0-5 years of age maximum serum creatinine (mg/dL) of 0.8; 6-10 years of age maximum serum creatinine (mg/dL) of 1.0; 11-14 years of age maximum serum creatinine (mg/dL) of 1.2;
10. Adequate bone marrow function:

    Absolute neutrophil count lower than 1 × 109/L;
11. History of a malignancy within 5 years;
12. HIV infection or known immunodeficiency;
13. Indication for treatment with corticosteroids, vincristine, interferon-α, sirolimus, or tacrolimus for an indication other than IH;
14. Patients with an inability to participate in or follow-up during the study treatment and assessment plan;
15. Inability to give informed consent.

Where it's running

• West China Hospital of Sichuan University
  Chengdu, Sichuan, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry and biobank for lymphatic malformations in Italy

  This study is creating a registry and biobank to collect information and samples from people with lymphatic malformations in Italy to improve understanding and treatment of these rare conditions.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT06892964

• Using Bleomycin for treating lymphatic malformations in children

  This study is testing whether different strengths of Bleomycin can safely treat lymphatic malformations in children under 14 that can't be removed with surgery.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT06437158

• Using indocyanine green imaging to treat cystic lymphatic malformation in children

  This study tests if using a special imaging technique can help doctors treat cystic lymphatic malformation in children better than traditional surgery alone.

  Recruiting Nanjing Children's Hospital · Nanjing, Jiangsu · NCT06275022

• Targeted therapies for patients with vascular malformations

  This study is testing new targeted treatments for patients with slow-flow and fast-flow vascular malformations to see if they work better than the usual therapies.

  Recruiting at 2 sites Phase 2 Murdoch Childrens Research Institute · Parkville, Victoria and 1 other locations · NCT05983159

• Treatment of lymphatic malformations in children using TARA-002

  This study is testing if a new treatment called TARA-002 can safely help reduce lymphatic malformations in children aged 6 months to under 18 years.

  Recruiting at 9 sites Phase 2 Protara Therapeutics · Birmingham, Alabama and 10 other locations · NCT05871970

• Weekly treatment with sirolimus for venous and lymphatic malformations

  This study is testing if giving sirolimus once a week can help people with venous and lymphatic malformations feel better while causing fewer side effects than taking it every day.

  Recruiting Phase 2 Medical University of South Carolina · Charleston, South Carolina · NCT04861064

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.